Guided by nature
Our Approach and Pipeline
Novel, first-in-class remyelination therapies
Rewind Therapeutics´ highly experienced, international team has established a leading-edge knowledge base in the field of remyelination. The Company aims to decipher and re-establish the process of remyelination in patients suffering from major neuronal diseases and injuries. Although the causes and types of demyelination vary, the repair process is identical and regarded as a necessary element for successful nerve protection therapy. This approach opens significant therapeutic potential for a broad range of demyelination-induced disease.
To date, Rewind Therapeutics has established an extensive knowledge base and IP estate on novel, first-in-class remyelination therapies. The approach is focused on ensuring proper functioning of myelinating oligodendrocytes and oligodendrocyte precursor cells (OPCs), drivers of the myelination process.
Rewind Therapeutics is currently advancing its preclinical lead candidate whilst building an innovative pipeline of novel, proprietary remyelination compounds.